Eligard®: Pharmacokinetics, effect on testosterone and PSA levels and tolerability

European Urology, Supplements

Volumn 4, Issue 5, 2005, Pages 20-25

  Berges, Richard ^a  

^a PAN Klinik am Neumarkt   (Germany)

Author keywords

Adverse events; Eligard ; Leuprolide; Pharmacokinetics; PSA level; Testosterone level; Tolerability

Indexed keywords

LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CASTRATION; CLINICAL TRIAL; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RESPONSE; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; EARLY CANCER; ERYTHEMA; FATIGUE; GYNECOMASTIA; HOT FLUSH; HUMAN; INJECTION SITE REACTION; LIBIDO DISORDER; MALAISE; MALE; METASTASIS; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; SKIN IRRITATION; TESTIS ATROPHY; TESTOSTERONE BLOOD LEVEL; URINARY DYSFUNCTION;

EID: 20344364659     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2005.04.001     Document Type: Article

References (26)

1. C. Huggins, and C.V. Hodges Studies on prostate cancer I. The effects of castration, estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 1941 293 297
2. H. Miyamoto, E.M. Messing, and C. Chang Androgen deprivation therapy for prostate cancer: current status and future prospects The Prostate 9999 2004 1 22
3. B.A. Hellerstedt, and K.J. Pienta The current state of hormone therapy for prostate cancer Ca Cancer J Clin 52 2002 154 179
4. R. Sharifi, L.D. Knoll, J. Smith, and E. Kramolowksy Leuprolide acetate (30 mg depot every four months) in the treatment of advanced prostate cancer Urology 51 1998 271 276
5. G. Tolis, D. Ackman, A. Stellos, A. Mehta, F. Labrie, and A.T. Fazekas Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists Proc Natl Acad Sci USA 79 1982 1658 1662
6. M.G. Oefelein, A. Feng, M.J. Scolieri, D. Ricchiutti, and M.I. Resnick Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making Urology 56 2000 1021 1024
7. L.M. Gommersall, D. Hayne, I.S. Shergill, M. Arya, and DM.A. Wallace Luteinising hormone releasing hormone analogues in the treatment of prostate cancer Expert Opin Pharmacother 3 2002 1685 1692
8. M.G. Oefelein, and R. Cornum Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm J Urol 164 2000 726 729
9. J. Kawakami, A. Morales, and O.N. Kingston A comprehensive evaluation in patients with cancer of the prostate on androgen suppression with LHRH agonists J Urol 176 2002 288 (abs 1135)
10. D. McLeod, N. Zinner, K. Tomera, D. Gleason, N. Fotheringham, and M. Campion A phase 3: multicentre open-label randomized study of abarelix versus leuprolide acetate in men with prostate cancer Urology 58 2001 756 761
11. S. Esquena, J.M. Abascal, E. Trilla, and J. Morote Failure of luteinising hormone releasing hormone agonist therapy to achieve castration. Does it exist? Eur Urol Suppl 3 2004 57 (abs 218)
12. R. Sharifi, R. Browneller Leuprolide Study Group Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer J Urol 168 2002 1001 1004
13. M.S. Khan, and A. O'Brien An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate Urol Int 60 1998 33 40
14. M.F. Sarosdy, P.F. Schellhammer, M.S. Soloway, N.J. Vogelzang, E.D. Crawford, and J. Presti Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer BJU Int. 83 1999 801 806
15. N. Zinner, M. Bidair, A. Centeno, and K. Tomera Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial Urology 64 2004 1177 1181
16. F.M. Chu, M. Jayson, M.K. Dineen, R. Perez, R. Harkaway, and R.C. Tyler A clinical study of 22.5 mg LA-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer J Urol 168 2002 1199 1203
17. R. Sharifi, M. Soloway Leuprolide study group Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer J Urol 143 1990 68 71
18. R. Perez-Marreno, F.M. Chu, D. Gleason, E. Loizides, B. Wachs, and R.C. Tyler A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer Clin Ther 24 2002 1902 1914
19. P. Periti, T. Mazzei, and E. Mini Clinical pharmacokinetics of depot leuprolelin Clin Pharmacokinet 41 2002 485 504
20. R. Perez-Marreno, and R.C. Tyler A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer Expert Opin Pharmacother 5 2004 447 457
21. ® 30.0 mg label.
22. B. Tombal Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: what is the optimal level of testosterone? Eur Urol 4 5 Suppl 2005 14 19
23. M.G. Oefelein, and M.I. Resnick Effective testosterone suppression for patients with prostate cancer: is there a best castration? Urology 62 2003 207 221
24. D. Fontana, M. Mari, A. Martinelli, C. Boccafoschi, C. Magno, and M. Turriziani 3-month formulation of goserelin acetate (Zoladex) in advanced prostate cancer: results from an Italian open multicentre trial Urol Int 70 2003 316 320
25. T. Nishiyama, S. Kanazawa, R. Watanabe, M. Terunuma, and K. Takahashi Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy Int J Urol 11 2004 735 741
26. O. Sartor Eligard: leuprolide acetate in a novel sustained-release delivery system Urology 61 Suppl. A 2003 25 31